A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Public ClinicalTrials.gov record NCT07419295. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.
Study identification
- NCT ID
- NCT07419295
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 590 participants
Conditions and interventions
Conditions
Interventions
- Sacituzumab tirumotecan Biological
- Vinflunine Drug
- Docetaxel Drug
- Paclitaxel Drug
- Rescue medications for sacituzumab tirumotecan Drug
- Rescue medications for chemotherapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2026 (Actual)
- Primary completion
- Jul 27, 2029 (Estimated)
- Completion
- Apr 23, 2030 (Estimated)
- Last update posted
- Oct 13, 2026
2026 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sibley Memorial Hospital ( Site 0849) | Washington D.C. | District of Columbia | 20016 | Recruiting |
| Emory University Hospital ( Site 0824) | Atlanta | Georgia | 30322 | Recruiting |
| Johns Hopkins University ( Site 0843) | Baltimore | Maryland | 21287 | Recruiting |
| Dana Farber Cancer Institute ( Site 0783) | Boston | Massachusetts | 02215 | Recruiting |
| Munson Medical Center ( Site 0812) | Traverse City | Michigan | 49684 | Recruiting |
| Morristown Memorial Hospital ( Site 0795) | Morristown | New Jersey | 07960 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 0832) | New York | New York | 10065 | Recruiting |
| WakeMed Raleigh Campus ( Site 0811) | Raleigh | North Carolina | 27610 | Recruiting |
| TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822) | Cincinnati | Ohio | 45220 | Recruiting |
| Cleveland Clinic - Ohio ( Site 0793) | Cleveland | Ohio | 44195 | Recruiting |
| Fox Chase Cancer Center ( Site 0830) | Philadelphia | Pennsylvania | 19111 | Recruiting |
| The West Clinic, P.C. ( Site 0791) | Germantown | Tennessee | 38138 | Recruiting |
| Thompson Cancer Survival Center ( Site 0803) | Knoxville | Tennessee | 37916 | Recruiting |
| Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0831) | Nashville | Tennessee | 37203 | Recruiting |
| Virginia Oncology Associates (VOA) ( Site 8002) | Norfolk | Virginia | 23502 | Recruiting |
| Fred Hutchinson Cancer Research Center ( Site 0787) | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07419295, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07419295 live on ClinicalTrials.gov.